AtheroGenics Plans Second Phase III Diabetes Study For AGI-1067
This article was originally published in The Pink Sheet Daily
Executive Summary
Interim analysis from ongoing ANDES trials shows Atlanta firm’s type 2 diabetes candidate significantly reduced hemoglobin A1c reduction.
You may also be interested in...
AtheroGenics Completes Enrollment Of Phase III AGI-1067 Diabetes Study
Interim data from the randomized, double-blind, placebo-controlled trial are expected in the second quarter of 2008.
AtheroGenics Discontinues High Dose Of AGI-1067 In Diabetes Trial Due To Liver Toxicity
ANDES trial will continue to evaluate the 75 mg and 150 mg doses of AGI-1067 after termination of 300 mg dosing.
Atherogenics Switches Focus For AGI-1067 To Glycemic Control In Diabetes
Atherogenics will begin looking for a new partner for the former atherosclerosis treatment, firm tells “The Pink Sheet” DAILY.